Axa S.A. Sells 3,282 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Axa S.A. cut its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 26.9% during the 4th quarter, HoldingsChannel reports. The firm owned 8,913 shares of the specialty pharmaceutical company’s stock after selling 3,282 shares during the period. Axa S.A.’s holdings in Collegium Pharmaceutical were worth $255,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. New Age Alpha Advisors LLC bought a new stake in shares of Collegium Pharmaceutical in the 4th quarter worth approximately $40,000. KBC Group NV increased its position in Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after buying an additional 982 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 316 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock worth $196,000 after acquiring an additional 642 shares in the last quarter. Finally, Aigen Investment Management LP purchased a new stake in shares of Collegium Pharmaceutical in the fourth quarter worth $230,000.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 1,949 shares of the firm’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the sale, the chief financial officer now directly owns 177,195 shares of the company’s stock, valued at $5,315,850. This trade represents a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the company’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the transaction, the executive vice president now directly owns 154,204 shares of the company’s stock, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 81,693 shares of company stock worth $2,334,994. 2.51% of the stock is owned by company insiders.

Collegium Pharmaceutical Stock Up 5.9 %

COLL opened at $28.89 on Friday. The stock has a market capitalization of $928.29 million, a price-to-earnings ratio of 12.45 and a beta of 0.63. The firm has a 50 day moving average price of $28.10 and a 200-day moving average price of $30.03. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on COLL shares. Piper Sandler reiterated a “neutral” rating and issued a $37.00 price target (up previously from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 19th. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.80.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.